+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alzheimer's Blood Tests Market by Test Type (Immunoassay, Mass Spectrometry, Next Generation Sequencing), Biomarker Class (Amyloid Beta, Neurofilament Light Chain, Tau Proteins), Technology Platform, Application, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Alzheimer's Blood Tests Market by Test Type (Immunoassay, Mass Spectrometry, Next Generation Sequencing), Biomarker Class (Amyloid Beta, Neurofilament Light Chain, Tau Proteins), Technology Platform, Application, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
New

Alzheimer's Blood Tests Market by Test Type (Immunoassay, Mass Spectrometry, Next Generation Sequencing), Biomarker Class (Amyloid Beta, Neurofilament Light Chain, Tau Proteins), Technology Platform, Application, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6147347
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Pioneering Blood-Based Diagnostics for Alzheimer’s Disease Revolutionizing Early Detection Through Cutting Edge Biomarker Analysis and Technology Integration

Early detection of Alzheimer’s disease has long posed a formidable challenge for clinicians, researchers, and patients alike. Historically, reliance on neuroimaging and cerebrospinal fluid analysis has restricted timely diagnosis by virtue of cost, invasiveness, and limited accessibility. In recent years, however, the convergence of biomarker science and advanced analytical technologies has ushered in the era of blood-based diagnostics. This shift promises to democratize access to testing by offering a minimally invasive, scalable solution capable of detecting pathophysiological changes well before clinical symptoms manifest.

Innovations in immunoassay sensitivity, digital polymerase chain reaction, and mass spectrometry have each contributed to unprecedented specificity in identifying hallmark proteins such as amyloid beta isoforms, tau species, and neurofilament light chain. Moreover, integration of microfluidic platforms and label-free biosensing has further accelerated assay throughput while reducing per-test costs. As a result, research institutions, diagnostic laboratories, and point-of-care settings are increasingly equipped to participate in large-scale screening efforts. The following sections delve into the transformative shifts, regulatory and economic factors, segmentation insights, and actionable strategies shaping the future of Alzheimer’s blood testing.

Emerging Paradigms in Alzheimer’s Testing Transforming Research and Clinical Practice Through Innovative Platforms and Enhanced Diagnostic Sensitivities

The landscape of Alzheimer’s diagnostics is undergoing seismic changes as traditional paradigms give way to novel technologies that enhance sensitivity, speed, and accessibility. Whereas imaging modalities provided invaluable insights into cerebral amyloidosis and neurodegeneration, their cost and logistical constraints limited population-level screening. In contrast, next generation sequencing, electrochemiluminescence immunoassays, and lateral flow devices are now enabling rapid, point-of-care assessments that bridge the gap between research and clinical application.

Furthermore, pharmaceutical and biotechnology collaborations are fueling accelerated validation studies, while regulatory agencies are introducing expedited pathways to evaluate breakthrough diagnostics. These developments have fostered an environment in which assay developers prioritize multiplexed biomarker panels that capture the multifactorial nature of Alzheimer’s pathology. Concurrently, investments in microfluidics and optical biosensor technologies are delivering handheld devices with laboratory-grade performance, thus redefining the boundaries of early detection and continuous monitoring.

Assessing the Long Term Consequences of Upcoming United States Trade Tariffs on Alzheimer’s Blood Testing Infrastructure and Industry Viability

Anticipated tariffs on imported reagents and instrumentation in 2025 present a complex challenge for stakeholders in Alzheimer’s blood test development. With critical components sourced globally, rising duties could drive up assay costs, constrain supply chains, and necessitate recalibration of pricing strategies. Producers may face delays in equipment deployment, potentially slowing the adoption of next generation sequencing platforms and mass spectrometry workflows that rely on specialized consumables.

In response, organizations are exploring strategies to mitigate disruption. These include diversifying supplier networks, investing in domestic manufacturing capabilities, and negotiating long-term agreements to lock in favorable pricing. Additionally, technological innovation offers a path to resilience: modular assay designs that leverage open-source reagents and in-house calibration standards can reduce dependence on high-tariff imports. As a result, companies that proactively adapt their sourcing and manufacturing frameworks will be best positioned to maintain continuity of research and clinical services in the face of evolving trade policies.

Revealing Core Segmentation Dynamics Across Test Types Biomarker Classes Platforms Applications End Users and Distribution Channels in Alzheimer’s Blood Testing

The Alzheimer’s blood test market is defined by multifaceted segmentation that guides product development and commercialization strategies. Based on test type, immunoassay platforms-including chemiluminescence immunoassay, electrochemiluminescence, ELISA, and lateral flow assays-remain predominant due to their balance of sensitivity and throughput, while mass spectrometry approaches such as GC-MS, LC-MS/MS, and MALDI-TOF offer unparalleled specificity for multiplexed biomarker detection. Next generation sequencing strategies, encompassing both targeted sequencing and whole genome sequencing, are gaining traction for their ability to elucidate genetic predispositions and variant profiles, whereas polymerase chain reaction techniques like digital PCR and qPCR deliver precise quantification of low-abundance targets.

Biomarker class segmentation further refines the market landscape, with amyloid beta species (Abeta40 and Abeta42), neurofilament light chain, and tau protein subtypes (phosphorylated tau and total tau) each playing distinct roles in early diagnosis, disease monitoring, and therapeutic evaluation. Technology platforms such as electrochemical sensors, label-free biosensors, microfluidics, and optical biosensors influence assay miniaturization and cost efficiency, while applications span disease monitoring, drug development support, and early diagnosis. End users range from diagnostic laboratories and research institutes to hospitals, clinics, and emerging home care settings, each demanding tailored workflows. Finally, distribution channels-whether direct sales, distribution partnerships, or online platforms-shape go-to-market dynamics and accessibility.

Mapping Regional Demand Drivers and Strategic Opportunities for Alzheimer’s Blood Diagnostics Across the Americas Europe Middle East & Africa and Asia-Pacific

Regional nuances in healthcare infrastructure, regulatory frameworks, and demographic trends drive distinct opportunities and challenges for Alzheimer’s blood diagnostics providers. In the Americas, established reimbursement models, robust clinical trial networks, and high public awareness create fertile ground for rapid adoption of cutting-edge assays. Key metropolitan centers serve as early adopters, catalyzing diffusion of technology into peripheral regions.

Across Europe, Middle East & Africa, regulatory harmonization initiatives and pan-continental consortia are accelerating multicenter validation studies, while variations in healthcare funding models require flexible pricing and market entry strategies. Collaborative research programs in the European Union and patient registries in the Middle East are expanding sample accessibility and data sharing, thereby supporting assay refinement.

In the Asia-Pacific region, demographic shifts toward aging populations and increasing healthcare expenditure are driving governments to prioritize early detection programs. Local manufacturing incentives and domestic R&D investments enable emerging players to introduce home-based testing kits and telemedicine-compatible platforms. Together, these regional drivers underscore the need for tailored market approaches that align with localized demand dynamics.

Highlighting Organizational Strategies and Collaborative Innovations Driving Leadership and Competitive Differentiation in Alzheimer’s Blood Testing

Leading organizations in the Alzheimer’s blood testing space are distinguished by their strategic alliances, technology integrations, and portfolio diversification efforts. Some firms have leveraged collaborations with academic medical centers to validate novel biomarkers and streamline regulatory submissions, while others have pursued acquisitions of specialized biosensor startups to amplify their point-of-care capabilities. Joint ventures between diagnostic developers and pharmaceutical companies are facilitating co-development of companion diagnostics for emerging therapeutics, enhancing clinical trial efficiency and therapeutic monitoring.

In parallel, technology enterprises are merging capabilities-combining microfluidic design with optical biosensing to create handheld devices capable of multiplexed analyses at the patient bedside. Research institutes and CRO partnerships have expanded longitudinal cohort studies, enabling real-world evidence generation and post-market surveillance. As competitive differentiation evolves, the ability to integrate data analytics platforms with laboratory information systems is emerging as a key success factor, driving seamless reporting and interpretation of biomarker results.

Strategic Imperatives and Practical Frameworks for Industry Leaders to Accelerate Adoption and Drive Sustainable Growth in Alzheimer’s Blood Test Development

Industry leaders can capitalize on emerging trends by adopting a set of strategic imperatives designed to accelerate market penetration and sustain growth. Prioritizing investment in high-sensitivity assay development will enhance diagnostic confidence, while modular platform designs facilitate rapid adaptation to newly identified biomarkers. Diversification of supply chains through regional manufacturing partnerships will mitigate geopolitical risks and ensure continuity of reagent availability.

Moreover, engaging proactively with regulatory bodies to define streamlined approval pathways can reduce time to market and establish first-mover advantages. Forming consortia with pharmaceutical developers and patient advocacy groups will bolster clinical validation efforts and foster stakeholder alignment. Finally, expanding into home care environments through user-friendly test kits and digital result reporting will broaden the reach of blood-based diagnostics, empowering earlier intervention and improved patient outcomes.

Comprehensive Research Methodology Integrating Qualitative and Quantitative Approaches to Ensure Robust Alzheimer’s Blood Test Market Insights and Validity

This analysis synthesizes qualitative interviews with leading clinicians, diagnostics developers, and regulatory experts, alongside quantitative surveys of end users and secondary data from peer-reviewed publications and patent filings. Data collection commenced with a systematic literature review to map existing biomarkers, assay platforms, and market trends. Key opinion leaders provided insights through structured interviews, yielding context on unmet needs and technology performance criteria.

These primary inputs were triangulated with quantitative survey results to validate adoption drivers and perceived barriers across different laboratory settings and geographic regions. A rigorous data validation process, including peer review and methodological audits, ensured the robustness of findings. Scenario modeling techniques assessed potential impacts of policy shifts-such as tariff implementations-while sensitivity analyses tested the resilience of strategic recommendations under varying assumptions.

Synthesis of Key Findings Reinforcing the Transformative Potential of Blood Based Alzheimer’s Diagnostics to Revolutionize Early Detection and Patient Outcomes

In synthesizing the key findings, it is clear that blood-based diagnostics are poised to redefine the paradigm of Alzheimer’s detection and management. The convergence of advanced immunoassays, sequencing technologies, and biosensor platforms has created an ecosystem capable of delivering unprecedented diagnostic accuracy in minimally invasive formats. As trade policy shifts and regional dynamics reshape the supply chain and market access, organizations that integrate strategic segmentation insights and collaborative innovation will emerge as leaders.

Ultimately, the transformative potential of these technologies extends beyond early diagnosis. By enabling continuous monitoring and facilitating patient stratification in clinical trials, blood-based tests hold the promise of accelerating therapeutic breakthroughs and improving quality of life for individuals at risk. Moving forward, the intersection of technological prowess, regulatory agility, and patient-centric deployment will determine which stakeholders successfully navigate this dynamic landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Test Type
    • Immunoassay
      • Chemiluminescence Immunoassay
      • Electrochemiluminescence
      • ELISA
      • Lateral Flow Assay
    • Mass Spectrometry
      • GC-MS
      • LC-MS/MS
      • MALDI-TOF
    • Next Generation Sequencing
      • Targeted Sequencing
      • Whole Genome Sequencing
    • Polymerase Chain Reaction
      • Digital PCR
      • qPCR
  • Biomarker Class
    • Amyloid Beta
      • Abeta40
      • Abeta42
    • Neurofilament Light Chain
    • Tau Proteins
      • Phosphorylated Tau
      • Total Tau
  • Technology Platform
    • Electrochemical Sensors
    • Label Free Biosensors
    • Microfluidics
    • Optical Biosensors
  • Application
    • Disease Monitoring
    • Drug Development Support
    • Early Diagnosis
  • End User
    • Diagnostic Laboratories
    • Home Care Settings
    • Hospitals And Clinics
    • Research Institutes
  • Distribution Channel
    • Direct Sales
    • Distributors
    • Online Channel
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Roche Diagnostics GmbH
  • Fujirebio Holdings, Inc.
  • Quanterix Corporation
  • C2N Diagnostics, Inc.
  • Siemens Healthineers AG
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • LumiraDx International Limited
  • PerkinElmer, Inc.
  • ADx Neurosciences, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in ultra-sensitive blood biomarkers for early detection of Alzheimer's disease
5.2. Integration of machine learning algorithms to analyze plasma protein patterns in Alzheimer's diagnosis
5.3. Regulatory approval pathways accelerating commercialization of novel blood tests for Alzheimer's screening
5.4. Collaborative partnerships between diagnostic companies and academic research centers for biomarker validation in Alzheimer's
5.5. Cost effectiveness and reimbursement strategies shaping market access for Alzheimer's blood test innovations
5.6. Emergence of multiplex panels combining amyloid and tau markers for comprehensive Alzheimer's disease assessment
5.7. Impact of decentralized testing models and point of care devices on Alzheimer's blood test adoption in clinical practice
5.8. Influence of population genomics and personalized medicine on the development of targeted Alzheimer's blood assays
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Alzheimer's Blood Tests Market, by Test Type
8.1. Introduction
8.2. Immunoassay
8.2.1. Chemiluminescence Immunoassay
8.2.2. Electrochemiluminescence
8.2.3. ELISA
8.2.4. Lateral Flow Assay
8.3. Mass Spectrometry
8.3.1. GC-MS
8.3.2. LC-MS/MS
8.3.3. MALDI-TOF
8.4. Next Generation Sequencing
8.4.1. Targeted Sequencing
8.4.2. Whole Genome Sequencing
8.5. Polymerase Chain Reaction
8.5.1. Digital PCR
8.5.2. qPCR
9. Alzheimer's Blood Tests Market, by Biomarker Class
9.1. Introduction
9.2. Amyloid Beta
9.2.1. Abeta40
9.2.2. Abeta42
9.3. Neurofilament Light Chain
9.4. Tau Proteins
9.4.1. Phosphorylated Tau
9.4.2. Total Tau
10. Alzheimer's Blood Tests Market, by Technology Platform
10.1. Introduction
10.2. Electrochemical Sensors
10.3. Label Free Biosensors
10.4. Microfluidics
10.5. Optical Biosensors
11. Alzheimer's Blood Tests Market, by Application
11.1. Introduction
11.2. Disease Monitoring
11.3. Drug Development Support
11.4. Early Diagnosis
12. Alzheimer's Blood Tests Market, by End User
12.1. Introduction
12.2. Diagnostic Laboratories
12.3. Home Care Settings
12.4. Hospitals And Clinics
12.5. Research Institutes
13. Alzheimer's Blood Tests Market, by Distribution Channel
13.1. Introduction
13.2. Direct Sales
13.3. Distributors
13.4. Online Channel
14. Americas Alzheimer's Blood Tests Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Alzheimer's Blood Tests Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Alzheimer's Blood Tests Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Roche Diagnostics GmbH
17.3.2. Fujirebio Holdings, Inc.
17.3.3. Quanterix Corporation
17.3.4. C2N Diagnostics, Inc.
17.3.5. Siemens Healthineers AG
17.3.6. Abbott Laboratories
17.3.7. Becton, Dickinson and Company
17.3.8. LumiraDx International Limited
17.3.9. PerkinElmer, Inc.
17.3.10. ADx Neurosciences, Inc.
18. Research AI19. Research Statistics20. Research Contacts21. Research Articles22. Appendix
List of Figures
FIGURE 1. ALZHEIMER'S BLOOD TESTS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ALZHEIMER'S BLOOD TESTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ALZHEIMER'S BLOOD TESTS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ALZHEIMER'S BLOOD TESTS MARKET: RESEARCHAI
FIGURE 28. ALZHEIMER'S BLOOD TESTS MARKET: RESEARCHSTATISTICS
FIGURE 29. ALZHEIMER'S BLOOD TESTS MARKET: RESEARCHCONTACTS
FIGURE 30. ALZHEIMER'S BLOOD TESTS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ALZHEIMER'S BLOOD TESTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY ELECTROCHEMILUMINESCENCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY ELECTROCHEMILUMINESCENCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY ELISA, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY GC-MS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY GC-MS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY LC-MS/MS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY LC-MS/MS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MALDI-TOF, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MALDI-TOF, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY QPCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY ABETA40, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY ABETA40, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY ABETA42, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY ABETA42, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEUROFILAMENT LIGHT CHAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEUROFILAMENT LIGHT CHAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY PHOSPHORYLATED TAU, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY PHOSPHORYLATED TAU, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TOTAL TAU, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TOTAL TAU, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY ELECTROCHEMICAL SENSORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY ELECTROCHEMICAL SENSORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY LABEL FREE BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY LABEL FREE BIOSENSORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY OPTICAL BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY OPTICAL BIOSENSORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISEASE MONITORING, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISEASE MONITORING, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DRUG DEVELOPMENT SUPPORT, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DRUG DEVELOPMENT SUPPORT, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY EARLY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY EARLY DIAGNOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 157. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 158. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 159. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 160. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 161. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 162. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 163. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 164. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 165. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 166. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 167. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2018-2024 (USD MILLION)
TABLE 168. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2025-2030 (USD MILLION)
TABLE 169. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2018-2024 (USD MILLION)
TABLE 170. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2025-2030 (USD MILLION)
TABLE 171. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2018-2024 (USD MILLION)
TABLE 172. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2025-2030 (USD MILLION)
TABLE 173. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 174. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 175. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 176. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 177. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. CANADA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 182. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 183. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 184. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 185. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 186. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 187. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 188. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 189. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 190. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 191. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2018-2024 (USD MILLION)
TABLE 192. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2025-2030 (USD MILLION)
TABLE 193. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2018-2024 (USD MILLION)
TABLE 194. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2025-2030 (USD MILLION)
TABLE 195. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2018-2024 (USD MILLION)
TABLE 196. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2025-2030 (USD MILLION)
TABLE 197. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 198. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 199. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 200. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 201. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. MEXICO ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY AMYLOID BETA, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TAU PROTEINS, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. GERMANY ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 304. GERMANY ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 305. GERMANY ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 306. GERMANY ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 307. GERMANY ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 308. GERMANY ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 309. GERMANY ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 310. GERMANY ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 311. GERMANY ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 312. GERMANY ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 313. GERMANY ALZHEIMER'S BLOOD TESTS MARKET SIZE, BY BIOMARKER CLASS, 2018-2024 (USD MILLION)
TABLE 314. GERMANY ALZHEIMER

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Alzheimer's Blood Tests Market report include:
  • Roche Diagnostics GmbH
  • Fujirebio Holdings, Inc.
  • Quanterix Corporation
  • C2N Diagnostics, Inc.
  • Siemens Healthineers AG
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • LumiraDx International Limited
  • PerkinElmer, Inc.
  • ADx Neurosciences, Inc.

Related Topics

Related Reports

Blood Tests for Alzheimer's Diagnosis Market by Product Type, Technology, Sample Type, End User, Disease Stage, Application - Global Forecast 2025-2030 - Product Image

Blood Tests for Alzheimer's Diagnosis Market by Product Type, Technology, Sample Type, End User, Disease Stage, Application - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Alzheimer's Disease Diagnosis Market by Product Type (Biomarker Assays, Cognitive Assessment Tools, Imaging Systems), End User (Diagnostic Laboratories, Home Care Settings, Hospitals), Technology, Disease Stage, Distribution Channel - Global Forecast 2025-2030 - Product Image

Alzheimer's Disease Diagnosis Market by Product Type (Biomarker Assays, Cognitive Assessment Tools, Imaging Systems), End User (Diagnostic Laboratories, Home Care Settings, Hospitals), Technology, Disease Stage, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Alzheimer'S Disease Diagnostics Market Size, Share & Trends Analysis Report by Diagnostics Technique (Biomarkers, Imaging Techniques, Genetic Testing), Type (Triage, Diagnosis, Screening), End-Use, and Region with Growth Forecasts, 2025-2030 - Product Image

Alzheimer'S Disease Diagnostics Market Size, Share & Trends Analysis Report by Diagnostics Technique (Biomarkers, Imaging Techniques, Genetic Testing), Type (Triage, Diagnosis, Screening), End-Use, and Region with Growth Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
U.S. Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Technique (Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests), By Type, By End-use, And Segment Forecasts, 2025 - 2030 - Product Image

U.S. Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Technique (Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests), By Type, By End-use, And Segment Forecasts, 2025 - 2030

  • Report
  • 80 Pages
  • United States
From
Alzheimer's Disease Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Alzheimer's Disease Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.